225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.
Machaba Michael SathekgeFrank BruchertseiferOtto KnoesenFlorette ReynekeIsmaheel LawalThabo LenganaCindy DavisJohncy MahapaneCeceila CorbettMariza VorsterAlfred MorgensternPublished in: European journal of nuclear medicine and molecular imaging (2018)
225Ac-PSMA-617 RLT of chemotherapy-naïve patients with advanced metastatic prostate carcinoma led to a ≥ 90% decline in serum PSA in 82% of patients including 41% of patients with undetectable serum PSA who remained in remission 12 months after therapy. The remarkable therapeutic efficacy reported in this study could be achieved with reduced toxicity to salivary glands due to de-escalation of administered activities in subsequent treatment cycles. This necessitates further exploration for informing clinical practice and clinical trial design.
Keyphrases
- prostate cancer
- radical prostatectomy
- clinical trial
- pet ct
- clinical practice
- end stage renal disease
- ejection fraction
- newly diagnosed
- pet imaging
- chronic kidney disease
- locally advanced
- squamous cell carcinoma
- small cell lung cancer
- open label
- peritoneal dialysis
- phase ii
- study protocol
- stem cells
- bone marrow
- radiation therapy
- mesenchymal stem cells
- ulcerative colitis
- cell therapy
- rectal cancer
- positron emission tomography